Gossamer Bio Completes Enrollment for Phase 3 PROSERA Study of PAH Drug Seralutinib
Gossamer Bio Inc. (NASDAQ:GOSS) is one of the best biotech stocks to invest in now. On June 16, Gossamer Bio announced the completion of enrollment for its global registrational Phase 3 PROSERA Study.